P09.27 Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)

Por Lombardi, G., Bellu, L.
Publicado no Neuro Oncol (2017)

Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art

Por Bergo, E., Lombardi, G., Pambuku, A., Della Puppa, A., Bellu, L., D'Avella, D., Zagonel, V.
Publicado no Biomed Res Int (2016)

P08.65 Evaluation of Clinical Benefit in patients treated with Bevacizumab

Por Villani, V., Fabi, A., Lombardi, G., Bellu, L., Zagonel, V., Carapella, C. M., Sperduti, I., Vidiri, A., Pace, A.
Publicado no Neuro Oncol (2016)

P09.29 Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center

Por Lombardi, G., Bellu, L., Pambuku, A., Fiduccia, P., Della Puppa, A., Gardiman, M., Berti, F., D’Avella, D., Zagonel, V.
Publicado no Neuro Oncol (2017)

P09.28 MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role

Por Lombardi, G., Bellu, L., Bertorelle, R., Pambuku, A., Gardiman, M., Fiduccia, P., Della Puppa, A., Berti, F., D’Avella, D., Zagonel, V.
Publicado no Neuro Oncol (2017)